- Report
- May 2024
- 131 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3560EUR$3,750USD£3,003GBP
- Report
- February 2021
- 420 Pages
United States
From €2278EUR$2,400USD£1,922GBP
- Report
- September 2018
- 174 Pages
Global
From €1305EUR$1,375USD£1,101GBP
€2611EUR$2,750USD£2,202GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2611EUR$2,750USD£2,202GBP
- Report
- August 2022
- 30 Pages
Global
From €3085EUR$3,250USD£2,603GBP
- Report
- March 2024
- 397 Pages
Global
From €7547EUR$7,950USD£6,366GBP
- Report
- February 2020
- 253 Pages
Global
From €5933EUR$6,250USD£5,005GBP
- Report
- March 2019
- 33 Pages
Global
€9493EUR$10,000USD£8,008GBP
Rexulti (brexpiprazole) is a medication used to treat mental disorders such as schizophrenia and bipolar disorder. It is an atypical antipsychotic drug that works by blocking certain receptors in the brain, which helps to reduce symptoms such as hallucinations, delusions, and disorganized thinking. Rexulti is also used to treat major depressive disorder, as well as irritability associated with autism.
Rexulti is available in both tablet and oral solution form, and is typically taken once daily. Common side effects of Rexulti include weight gain, drowsiness, and dizziness. It is important to note that Rexulti can interact with other medications, so it is important to discuss all medications with a healthcare provider before taking Rexulti.
The Rexulti market is a growing segment of the mental disorders drugs market. It is a competitive market, with several companies offering their own versions of the drug. Some of the companies in the Rexulti market include Otsuka Pharmaceuticals, Sunovion Pharmaceuticals, and Lundbeck. Show Less Read more